TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31028006

Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting healthful diet and physical activity
Number of subjects: 18

Group type: COMPARATOR
Intervention: Attention-matched control targeting sexual risk behaviors
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 18
Study: 28035924

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day) plus Choline Alphoscerate (1200 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Donepezil (10 mg/day) plus Placebo
Number of subjects: 113
Study: 26310362

Group type: EXPERIMENTAL
Intervention: Active Treatment Condition (ATC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist Control Condition (WLC)
Number of subjects: 59
Study: 23806882

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sevoflurane (SEVO) anesthesia
Number of subjects: 84
Study: 20932707

Group type: COMPARATOR
Intervention: ACL-PCL
Number of subjects: 440

Group type: COMPARATOR
Intervention: MP
Number of subjects: 440

Group type: COMPARATOR
Intervention: PS
Number of subjects: 440
Study: 19514089

Group type: EXPERIMENTAL
Intervention: EGF 50 microg/mL
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 17543813

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine as a bolus and/or 50‐hour infusion
Number of subjects: 233

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 233
Study: 15877015

Group type: EXPERIMENTAL
Intervention: 61% alcohol-ZPT product (waterless application)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 61% alcohol-ZPT product (water-aided application)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Commonly available handwashes (control)
Number of subjects: 49
Study: 12830748

Group type: EXPERIMENTAL
Intervention: Patient education during waiting time in the clinic (n = 104)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (n = 101)
Number of subjects: 205
Study: 15168718

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) plus Didanosine (ddI)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) plus Lamivudine (3TC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus Didanosine (ddI)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus Lamivudine (3TC)
Number of subjects: 3
Study: 8573702

Group type: EXPERIMENTAL
Intervention: Feedback of eye movements treatment (wearing glasses providing a reminder bleep if patients failed to move their eyes to the left in a 15 s interval) for 2 h 40 min a week for 4 weeks.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment for visual inattention).
Number of subjects: 18
Study: 2677240

Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Brofaromine (25 mg bid, 50 mg bid, 75 mg bid)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nomifensine 100 mg/day
Number of subjects: 124
Study: 860894

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride (N = 22)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride (N = 19)
Number of subjects: 41
Study: 31025876

Group type: EXPERIMENTAL
Intervention: T-4°C-15 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-4°C-30 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-4°C-60 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-4°C-120 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-24°C-15 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-24°C-30 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-24°C-60 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-24°C-120 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-4°C-15 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-4°C-30 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-4°C-60 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-4°C-120 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-24°C-15 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-24°C-30 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-24°C-60 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: AN-24°C-120 minutes
Number of subjects: 50
Study: 28575885

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 88
Study: 25050869

Group type: EXPERIMENTAL
Intervention: Amlodipin (5-10 mg/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Verapamil (120-240 mg/d)
Number of subjects: 41
Study: 23556460

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Psyllium (PSY)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fiber supplements (GA, PSY, CMC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21931737

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) rAd5 vaccine boost
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) rAd5 vaccine boost
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rAd5 vaccine boost
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not receiving rAd5 vaccine boost)
Number of subjects: 90
Study: 18348715

Group type: EXPERIMENTAL
Intervention: Gluten-free vegan diet
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vegan diet (responders)
Number of subjects: 66
Study: 17240799

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (radiotherapy plus injection cisplatin 30 mg/m2 once weekly for 5 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Radiotherapy alone (external radiotherapy of 5000 cGy in conventional fractionation followed by brachytherapy)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 160
Study: 12788885

Group type: EXPERIMENTAL
Intervention: 100 mg DHEA after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 16
Study: 11004057

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8972377

Group type: EXPERIMENTAL
Intervention: Saline injection (0.5 ml of balanced salt solution) for conjunctival wound closure (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual closure with Moorfields forceps (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saline injection (Group B)
Number of subjects: 40
Study: 1358607

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4089582

Group type: EXPERIMENTAL
Intervention: timolol (10 mg/d, n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: methyldopa (250 mg/d, n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg/d) and amiloride (2.5 mg/d)
Number of subjects: 30
Study: 29277138

Group type: EXPERIMENTAL
Intervention: Educational intervention (reading a brief informational pamphlet about ECT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 91
Study: 27138833

Group type: EXPERIMENTAL
Intervention: Bilateral rTMS (10 Hz left DLPFC, 1 Hz right DLPFC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unilateral rTMS (1 Hz right DLPFC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilateral rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unilateral rTMS
Number of subjects: 30
Study: 24463948

Group type: EXPERIMENTAL
Intervention: DVD (DVD format + standard care)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care (written anticipatory guidance handout and free talk)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DVD group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study: 22683613

Group type: EXPERIMENTAL
Intervention: Plerixafor plus granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study: 20236777

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study: 18377160

Group type: EXPERIMENTAL
Intervention: Sister‐to‐Sister intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16124423

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (initial dose of 40 mg/kg bodyweight, in 3 or 4 divided doses in the first 24 hours, followed by 10 mg/kg bodyweight once daily for three consecutive days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Rectal artesunate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (high initial dose regimen of 20 mg/kg bodyweight)
Number of subjects: 13
Study: 15311661

Group type: EXPERIMENTAL
Intervention: Using rigid finger sheath
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using rigid probe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing the number of end effectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearing a compliant finger cover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Splinting the fingers
Number of subjects: 0
Study: 10783940

Group type: EXPERIMENTAL
Intervention: Patient education and self-management plan
Number of subjects: 140
Study: 9269055

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual influenza vaccinations
Number of subjects: 0
Study: 8334064

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol 50 mg and nifedipine retard 20 mg (Tenif) once daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 63
Study: 3769183

Group type: EXPERIMENTAL
Intervention: Retrograde coronary sinus perfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anterograde aortic root perfusion
Number of subjects: 40
Study: 29775957

Group type: EXPERIMENTAL
Intervention: MAS‐XR (60mg or 80mg daily)
Number of subjects: 126
Study: 27132212

Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapeutic
Number of subjects: 2312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapeutic (no chemotherapy)
Number of subjects: 2312

Group type: COMPARATOR
Intervention: Placebo (no chemotherapy)
Number of subjects: 2312
Study: 24304291

Group type: EXPERIMENTAL
Intervention: 150 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 75 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9

Group type: COMPARATOR
Intervention: 905 ppm fluoride rinse alone
Number of subjects: 9
Study: 22276905

Group type: EXPERIMENTAL
Intervention: Limb dependency (lowering the limb from heart level to 30 cm below heart level)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Limb dependency
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sympathetic blockade (acute systemic sympathetic blockade)
Number of subjects: 34
Study: 20147846

Group type: EXPERIMENTAL
Intervention: Amiodarone (AMD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF)
Number of subjects: 30
Study: 19253734

Group type: EXPERIMENTAL
Intervention: External irradiation (25-60 Gy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No external irradiation
Number of subjects: 70
Study: 16023481

Group type: EXPERIMENTAL
Intervention: Neuropathic diabetic patients with claw/hammer toe deformity
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neuropathic diabetic controls without deformity
Number of subjects: 26
Study: 12538211

Group type: EXPERIMENTAL
Intervention: Perioperative epidural analgesia
Number of subjects: 915

Group type: COMPARATOR
Intervention: IV opioids
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 915

Group type: COMPARATOR
Intervention: Control group (IV opioids)
Number of subjects: 915
Study: 11778184

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVLX) at a dose of 300 mg/d
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ofloxacin (OFLX) at a dose of 600 mg/d
Number of subjects: 138
Study: 9017171

Group type: EXPERIMENTAL
Intervention: Alum mouthrinse (500 ppm Al) and placebo dentifrice
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Alum mouthrinse (500 ppm Al) and fluoride dentifrice (1100 ppm F)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo mouthrinse and fluoride dentifrice (1100 ppm F)
Number of subjects: 260
Study: 1634661

Group type: EXPERIMENTAL
Intervention: Adenosine (140 micrograms/kg per min for 6 min)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Exercise stress
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 175

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 175
Study: 6695025

Group type: EXPERIMENTAL
Intervention: Silicone-gel prostheses
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline-filled prostheses
Number of subjects: 37
Study: 30888975

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) measurement
Number of subjects: 170
Study: 29554282

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 1622
Study: 26773719

Group type: EXPERIMENTAL
Intervention: Good fitness level (maximum oxygen uptake > 25th percentile)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Poor fitness level (maximum oxygen uptake < 25th percentile)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Good fitness level
Number of subjects: 44

Group type: COMPARATOR
Intervention: Poor fitness level
Number of subjects: 44
Study: 24608457

Group type: EXPERIMENTAL
Intervention: 1 h continuous TCD‐US for MCA
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 42
Study: 22028294

Group type: EXPERIMENTAL
Intervention: Personalized therapy based on ERCC1 and RRM1 expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (Trial A, B, C)
Number of subjects: 0
Study: 20112404

Group type: EXPERIMENTAL
Intervention: Micro-CT scans in RA patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Micro-CT scans in healthy individuals
Number of subjects: 58
Study: 18074942

Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid (4 g myo-inositol plus 400 mcg folic acid)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (400 mcg folic acid)
Number of subjects: 92
Study: 15610252

Group type: EXPERIMENTAL
Intervention: BNP testing (diagnostic strategy with BNP levels)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (diagnostic strategy without BNP levels)
Number of subjects: 452
Study: 11971941

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 25
Study: 10435469

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 8672312

Group type: COMPARATOR
Intervention: Pregnant normotensive (NPIH)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pregnant patients with pregnancy-induced hypertension (PIH)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-pregnant (NP)
Number of subjects: 41
Study: 2296878

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg three times daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg three times daily
Number of subjects: 27
Study: 370420

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Imidazole‐carboxamide
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Imidazole‐carboxamide followed by cyclophosphamide
Number of subjects: 165
Study: 31115273

Group type: EXPERIMENTAL
Intervention: PPCS group (60 participants)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recovered mTBI group (30 participants)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control group (17 participants)
Number of subjects: 60
Study: 28394670

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) three times a week for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention, normal diet, usual exercise)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 30
Study: 25464907

Group type: EXPERIMENTAL
Intervention: UMEC 15.6 mcg once daily (OD)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg once daily (OD)
Number of subjects: 350

Group type: COMPARATOR
Intervention: UMEC (various doses)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 23305962

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Combination chemotherapy (in concurrent study)
Number of subjects: 78
Study: 21353673

Group type: EXPERIMENTAL
Intervention: 2.5 mg letrozole daily for 7 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 17
Study: 19152549

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nabumetone 1 g
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 15
Study: 17415139

Group type: EXPERIMENTAL
Intervention: Pulse therapy (300 mg dexamethasone for 3 consecutive days followed by 4 days of placebo)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control treatment (prednisone 70 mg per day tapered in steps of 10 mg per day to 0 mg)
Number of subjects: 81
Study: 16506546

Group type: EXPERIMENTAL
Intervention: DEC (12mg/kg body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DEC + Ivermectin 200mcg (6mg/kg body weight + 200 mcg/kg body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DEC + Ivermectin 400mcg (6mg/kg body weight + 400 mcg/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: DEC alone
Number of subjects: 60
Study: 17671254

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg each night) from 24 to 34 weeks of gestation
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg each night)
Number of subjects: 250
Study: 11090405

Group type: EXPERIMENTAL
Intervention: Unenhanced CT
Number of subjects: 93
Study: 8723580

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 or 600 IU/kg) administered three times (days 1, 4, and 7)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 1910162

Group type: EXPERIMENTAL
Intervention: Mailed computer-generated appointment reminders
Number of subjects: 901

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 901
Study: 6125676

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg and clavulanic acid 125 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg and clavulanic acid 250 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxycillin 500 mg
Number of subjects: 100
Study: 31975053

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) - eating <8 hours per day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31740545

Group type: EXPERIMENTAL
Intervention: MSC-NTF cells (n = 36)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 48
Study: 29573081

Group type: EXPERIMENTAL
Intervention: AGV surgery with subconjunctival Bevacizumab (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional AGV surgery (group 1)
Number of subjects: 50
Study: 26736036

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 25247908

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% + 1 μg/kg dexmedetomidine (Group BD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group BD
Number of subjects: 60
Study: 22475319

Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 258

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study: 20605648

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) - 100% oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Best standard care (control group)
Number of subjects: 58
Study: 18036976

Group type: EXPERIMENTAL
Intervention: Work to Tolerance (WTT) exercise group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Work to Quota (WTQ) exercise group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Comparison of WTT and WTQ groups
Number of subjects: 35